$0.310.00 (+0.52%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
EyePoint (EYPT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 32% below its peak, net margin −739.4%. Worth your attention in FY25: Share count (+115.2%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼27.5%
31.4
FY21→FY25CAGR −4.0%/yr
Net income ($M)▼77.2%
−232.0
FY21→FY25CAGR —
Free cash flow ($M)▼86.8%
−243.4
FY21→FY25CAGR —
Diluted EPS▼36.6%
−3.17
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+115.2%
34.0mn → 73.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$3.3M
−19.1% YoY in FY25 · 10.5% of revenue.
Returns vs FCF
n/m
$0.5M returned vs $−243.4M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-739¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -739.4% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 2,578.0 | 31,371.0 | 43,273.0 | 46,018.0 | 41,404.0 | 36,939.0 | ▼27.5% | −4.0% |
Cost of revenue | 375.0 | 2,066.0 | 0.0 | 0.0 | 8,326.0 | 8,177.0 | — | −29.1% |
Gross profit | 2,203.0 | — | — | — | 33,078.0 | 28,762.0 | — | — |
Research & development | 296,645.0 | 221,039.0 | 132,926.0 | 64,662.0 | 49,642.0 | 28,500.0 | ▲66.3% | +66.9% |
Selling, general & admin | 56,276.0 | 51,610.0 | 52,358.0 | 40,102.0 | 34,817.0 | 25,575.0 | ▼1.4% | +19.2% |
Total operating expenses | 354,031.0 | 272,739.0 | 189,127.0 | 121,085.0 | 132,715.0 | 84,038.0 | ▲44.2% | +34.2% |
Operating incomefeeds ROC rank | −351,828.0 | −243,434.0 | −145,854.0 | −75,067.0 | −99,637.0 | −55,276.0 | ▼66.9% | — |
Other income, net | 9,441.0 | 11,751.0 | 15,074.0 | 4,355.0 | −2,617.0 | −3,141.0 | — | — |
Pretax income | −342,387.0 | −231,683.0 | −130,780.0 | −70,712.0 | −102,254.0 | −58,417.0 | ▼77.2% | — |
Income tax | 136.0 | 279.0 | 90.0 | 83.0 | 0.0 | — | ▲210.0% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −342,523.0 | −231,962.0 | −130,870.0 | −70,795.0 | −102,254.0 | −58,417.0 | ▼77.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.97 | −3.17 | −2.32 | −1.82 | −2.74 | −2.03 | ▼36.6% | — |
Diluted shares (mn) | 89.25 | 73.25 | 56.30 | 38.90 | 37.32 | 34.04 | ▲30.1% | +21.1% |
| Margins | ||||||||
Gross margin75th pct in Healthcare | 85.5% | — | — | — | 79.9% | 77.9% | — | — |
Operating margin | −13647.3% | −776.0% | −337.1% | −163.1% | −240.6% | −149.6% | ▼438.9pp | −626.3pp |
Net margin10th pct in Healthcare | −13286.4% | −739.4% | −302.4% | −153.8% | −247.0% | −158.1% | ▼437.0pp | −581.3pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 11 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was EyePoint's revenue last fiscal year?
EyePoint reported revenue of $31.4M in fiscal 2025, down 27.5% from fiscal 2024.
What was EyePoint's net income?
EyePoint reported net income of −$232.0M in fiscal 2025, a net margin of −739.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

